Literature DB >> 26561565

Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Christine Johnston1, Lawrence Corey2.   

Abstract

Herpes simplex virus 2 (HSV-2) is a DNA virus that is efficiently transmitted through intimate genital tract contact and causes persistent infection that cannot be eliminated. HSV-2 may cause frequent, symptomatic self-limited genital ulcers, but in most persons infection is subclinical. However, recent studies have demonstrated that the virus is frequently shed from genital surfaces even in the absence of signs or symptoms of clinical disease and that the virus can be transmitted during these periods of shedding. Furthermore, HSV-2 shedding is detected throughout the genital tract and may be associated with genital tract inflammation, which likely contributes to increased risk of HIV acquisition. This review focuses on HSV diagnostics, as well as what we have learned about the importance of frequent genital HSV shedding for (i) HSV transmission and (ii) genital tract inflammation, as well as (iii) the impact of HSV-2 infection on HIV acquisition and transmission. We conclude with discussion of future areas of research to push the field forward.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26561565      PMCID: PMC4771215          DOI: 10.1128/CMR.00043-15

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  151 in total

1.  ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy.

Authors: 
Journal:  Obstet Gynecol       Date:  2007-06       Impact factor: 7.661

2.  Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010.

Authors:  Heather Bradley; Lauri E Markowitz; Theda Gibson; Geraldine M McQuillan
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

3.  Detection of a new variant of herpes simplex virus type 2 among HIV-1-infected individuals.

Authors:  Sonia Burrel; Emiliana P Abrao; Nathalie Désiré; Sophie Seang; Eric Caumes; Henri Agut; David Boutolleau
Journal:  J Clin Virol       Date:  2013-04-05       Impact factor: 3.168

4.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

5.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

6.  Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Authors:  Jairam R Lingappa; Jared M Baeten; Anna Wald; James P Hughes; Katherine K Thomas; Andrew Mujugira; Nelly Mugo; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; James Kiarie; Carey Farquhar; Grace John Stewart; Joseph Makhema; Myron Essex; Edwin Were; Kenneth H Fife; Guy de Bruyn; Glenda E Gray; James A McIntyre; Rachel Manongi; Saidi Kapiga; David Coetzee; Susan Allen; Mubiana Inambao; Kayitesi Kayitenkore; Etienne Karita; William Kanweka; Sinead Delany; Helen Rees; Bellington Vwalika; Amalia S Magaret; Richard S Wang; Lara Kidoguchi; Linda Barnes; Renee Ridzon; Lawrence Corey; Connie Celum
Journal:  Lancet       Date:  2010-02-12       Impact factor: 79.321

7.  Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses.

Authors:  Moira A McMahon; Teresa L Parsons; Lin Shen; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

8.  Correlate of immune protection against HSV-1 genital disease in vaccinated women.

Authors:  Robert B Belshe; Thomas C Heineman; David I Bernstein; Abbie R Bellamy; Marian Ewell; Robbert van der Most; Carolyn D Deal
Journal:  J Infect Dis       Date:  2013-11-27       Impact factor: 5.226

9.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

10.  Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples.

Authors:  A J Ryncarz; J Goddard; A Wald; M L Huang; B Roizman; L Corey
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

View more
  40 in total

1.  Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.

Authors:  Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

2.  IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis.

Authors:  Jameson K Gardner; Melissa M Herbst-Kralovetz
Journal:  Cytokine       Date:  2018-08-15       Impact factor: 3.861

Review 3.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.

Authors:  Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

Review 5.  Herpes Simplex Virus Latency Is Noisier the Closer We Look.

Authors:  Navneet Singh; David C Tscharke
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

Review 6.  CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?

Authors:  Harshana S De Silva Feelixge; Daniel Stone; Pavitra Roychoudhury; Martine Aubert; Keith R Jerome
Journal:  ACS Infect Dis       Date:  2018-03-21       Impact factor: 5.084

Review 7.  Epigenetics and Genetics of Viral Latency.

Authors:  Paul M Lieberman
Journal:  Cell Host Microbe       Date:  2016-05-11       Impact factor: 21.023

8.  The Effect of Hormonal Contraception and Menstrual Cycle Timing on Genital Herpes Simplex Virus-2 Shedding and Lesions.

Authors:  Elizabeth Micks; Hyunju Son; Amalia Magaret; Stacy Selke; Christine Johnston; Anna Wald
Journal:  Sex Transm Dis       Date:  2019-01       Impact factor: 2.830

9.  Supplementing the Diet with Sodium Propionate Suppresses the Severity of Viral Immuno-inflammatory Lesions.

Authors:  Deepak Sumbria; Engin Berber; Barry T Rouse
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

10.  Estradiol Enhances Antiviral CD4+ Tissue-Resident Memory T Cell Responses following Mucosal Herpes Simplex Virus 2 Vaccination through an IL-17-Mediated Pathway.

Authors:  Puja Bagri; Ramtin Ghasemi; Joshua J C McGrath; Danya Thayaparan; Emma Yu; Andrew G Brooks; Martin R Stämpfli; Charu Kaushic
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.